Suppr超能文献

新辅助化疗与新辅助放化疗治疗食管癌的疗效和生存:逆倾向评分加权分析。

Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.

机构信息

Department of Upper Gastrointestinal Surgery, University Hospital Southampton, Southampton, UK.

Department of Upper Gastrointestinal Surgery, University Hospital Southampton, Southampton, UK.

出版信息

Eur J Surg Oncol. 2020 Dec;46(12):2248-2256. doi: 10.1016/j.ejso.2020.06.038. Epub 2020 Jul 10.

Abstract

BACKGROUND

Esophageal cancer is increasingly common and carries a poor prognosis. The optimal treatment modality for locally advanced cancer is unknown, with current guidance recommending either neoadjuvant chemotherapy (CT) or chemoradiotherapy (CRT) followed by surgery. There is a lack of adequately powered trials comparing CT against CRT. We retrospectively compared CT versus CRT using a propensity score weighting approach.

METHODS

Demographic, disease, treatment and outcome data were retrieved from a local database for patients who received neoadjuvant CT or CRT followed by surgery. Inverse probability of treatment weighting (IPTW) was used to balance groups using a propensity score-weighting approach. Groups were assessed for differences in postoperative outcomes and survival. Kaplan-Meier and non-parametric tests were used to compare survival and outcome data as appropriate.

RESULTS

Data for 284 patients were retrieved. Following IPTW groups were well matched. No significant differences were seen for postoperative complications (CT 64.9% vs. CRT 63.3%, p = 0.807), including major complications (24.0% vs. 23.6%, p = 0.943) and anastomotic leak (7.8% vs. 5.6%, p = 0.526). Significantly higher rates of clinical regression and complete pathological response were seen following CRT (p = 0.002 for both). Rates of R0 resection were higher with CRT, CT 79.1% vs. CRT 93.1%, p = 0.006. There was no difference between groups for overall or disease-free survival.

CONCLUSION

This study suggests that the significant improvements in local tumour response seen after neoadjuvant CRT compared to CT may not translate to different survival outcomes. However, it must be stressed that adequately powered prospective trials are still lacking.

摘要

背景

食管癌的发病率越来越高,预后较差。局部晚期癌症的最佳治疗方式尚不清楚,目前的指南建议采用新辅助化疗(CT)或放化疗(CRT)联合手术。目前缺乏比较 CT 与 CRT 的充分有效的试验。我们采用倾向评分加权的方法,回顾性地比较了 CT 与 CRT。

方法

从当地数据库中检索接受新辅助 CT 或 CRT 联合手术的患者的人口统计学、疾病、治疗和结局数据。采用逆概率治疗加权(IPTW)通过倾向评分加权的方法来平衡组间差异。评估两组术后结局和生存的差异。Kaplan-Meier 和非参数检验用于比较生存和结局数据。

结果

共检索到 284 例患者的数据。经 IPTW 后,两组匹配良好。术后并发症(CT 组 64.9% vs. CRT 组 63.3%,p=0.807),包括严重并发症(24.0% vs. 23.6%,p=0.943)和吻合口漏(7.8% vs. 5.6%,p=0.526)无显著差异。CRT 后临床缓解和完全病理缓解的比例明显更高(均为 p=0.002)。CRT 组 R0 切除率更高,CT 组为 79.1%,CRT 组为 93.1%,p=0.006。两组总生存和无病生存无差异。

结论

本研究表明,与 CT 相比,新辅助 CRT 后局部肿瘤反应的显著改善可能不会转化为不同的生存结果。然而,必须强调的是,目前仍缺乏充分有效的前瞻性试验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验